Using imaging biomarkers to accelerate drug development and clinical trials.

[1]  E. Eisenhauer,et al.  Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. , 2004, Journal of the National Cancer Institute.

[2]  S. Feinstein,et al.  Role of surrogate markers in assessing patients with diabetes mellitus and the metabolic syndrome and in evaluating lipid-lowering therapy. , 2004, The American journal of cardiology.

[3]  Gunnar Antoni,et al.  Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant , 2004, Biological Psychiatry.

[4]  P. Calabresi,et al.  Interferon-&bgr;-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb− and NAb+ patients , 2004, Neurology.

[5]  S. Kapur,et al.  EMD 281014, a specific and potent 5HT2 antagonist in humans: a dose-finding PET study , 2004, Psychopharmacology.

[6]  D W Townsend,et al.  Physical principles and technology of clinical PET imaging. , 2004, Annals of the Academy of Medicine, Singapore.

[7]  Ricky T. Tong,et al.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer , 2004, Nature Medicine.

[8]  Markus Rudin,et al.  Magnetic resonance imaging in drug discovery: lessons from disease areas. , 2004, Drug discovery today.

[9]  J. Mocco,et al.  Serial magnetic resonance imaging in experimental primate stroke: Validation of MRI for pre-clinical cerebroprotective trials , 2003, Neurological research.

[10]  L. Durelli.  Dose and frequency of interferon treatment matter , 2003, Journal of Neurology.

[11]  Michal Neeman,et al.  Structural, functional, and molecular MR imaging of the microvasculature. , 2003, Annual review of biomedical engineering.

[12]  Reza Jahan,et al.  Assessment of the patient with hyperacute stroke: imaging and therapy. , 2003, Radiology.

[13]  G. Duyk.  Attrition and Translation , 2003, Science.

[14]  Harvey R Herschman,et al.  Molecular Imaging: Looking at Problems, Seeing Solutions , 2003, Science.

[15]  J Nuyts,et al.  18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). , 2003, European journal of cancer.

[16]  Bengt Långström,et al.  Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development , 2003, European Journal of Clinical Pharmacology.

[17]  M. Schwaiger,et al.  Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R. Hargreaves,et al.  Clinical biomarkers in drug discovery and development , 2003, Nature Reviews Drug Discovery.

[19]  R. Herbst,et al.  Surrogate markers in antiangiogenesis clinical trials , 2003, British Journal of Cancer.

[20]  U. Vanhoefer,et al.  Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584. , 2003, Seminars in oncology.

[21]  Richard Pazdur,et al.  End points and United States Food and Drug Administration approval of oncology drugs. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[23]  Gwenn S. Smith,et al.  Applications of neuroreceptor imaging to psychiatry research. , 2003, Psychopharmacology bulletin.

[24]  Vasilis Ntziachristos,et al.  Shedding light onto live molecular targets , 2003, Nature Medicine.

[25]  K. Miles,et al.  Functional computed tomography in oncology. , 2002, European journal of cancer.

[26]  A Gregory Sorensen,et al.  Predicting cerebral ischemic infarct volume with diffusion and perfusion MR imaging. , 2002, AJNR. American journal of neuroradiology.

[27]  J. Kalden,et al.  Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. , 2002, Arthritis and rheumatism.

[28]  J. Folkman,et al.  Clinical translation of angiogenesis inhibitors , 2002, Nature Reviews Cancer.

[29]  B. Lewis,et al.  Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFN&bgr;-1b , 2002, Neurology.

[30]  S. Gambhir.  Molecular imaging of cancer with positron emission tomography , 2002, Nature Reviews Cancer.

[31]  Alex Matter,et al.  Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug , 2002, Nature Reviews Drug Discovery.

[32]  Richard W. Martin,et al.  Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. , 2002, Arthritis and rheumatism.

[33]  F Barkhof,et al.  The role of MRI as a surrogate outcome measure in multiple sclerosis , 2002, Multiple sclerosis.

[34]  Martin G Pomper,et al.  Can small animal imaging accelerate drug development? , 2002, Journal of cellular biochemistry. Supplement.

[35]  R. Weissleder.  Scaling down imaging: molecular mapping of cancer in mice , 2002, Nature Reviews Cancer.

[36]  Nathaniel M. Alpert,et al.  Pharmacokinetic Imaging , 2002, Clinical pharmacokinetics.

[37]  M. Schwaiger,et al.  Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  G. Cosnard,et al.  Usefulness of Magnetic Resonance-Derived Quantitative Measurements of Cerebral Blood Flow and Volume in Prediction of Infarct Growth in Hyperacute Stroke , 2001, Stroke.

[39]  M. Rudin,et al.  From anatomy to the target: Contributions of magnetic resonance imaging to preclinical pharmaceutical research , 2001, The Anatomical record.

[40]  F. Buonanno,et al.  Predicting Tissue Outcome in Acute Human Cerebral Ischemia Using Combined Diffusion- and Perfusion-Weighted MR Imaging , 2001, Stroke.

[41]  Richard W. Martin,et al.  A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. , 2000, The New England journal of medicine.

[42]  Peter Reimer,et al.  Cerebral MR Perfusion Imaging: Principles and Current Applications , 2000 .

[43]  Geert Molenberghs,et al.  Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis , 2000, The Lancet.

[44]  M Slifstein,et al.  Validation and Reproducibility of Measurement of 5-HT1A Receptor Parameters with [carbonyl-11C]WAY-100635 in Humans: Comparison of Arterial and Reference Tissue Input Functions , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[45]  J. Nährig,et al.  Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  R. Temple,et al.  Are surrogate markers adequate to assess cardiovascular disease drugs? , 1999, JAMA.

[47]  T. Reese,et al.  In vivo magnetic resonance methods in pharmaceutical research: current status and perspectives , 1999, NMR in biomedicine.

[48]  B R Rosen,et al.  Hyperacute stroke: simultaneous measurement of relative cerebral blood volume, relative cerebral blood flow, and mean tissue transit time. , 1999, Radiology.

[49]  N. Alpert,et al.  The role of positron emission tomography in pharmacokinetic analysis. , 1997, Drug metabolism reviews.

[50]  R. Merrill.  The Architecture of Government Regulation of Medical Products , 1996 .

[51]  N. Alpert,et al.  Evaluation of cerebral pharmacokinetics of the novel antidepressant drug, BMS-181101, by positron emission tomography. , 1996, The Journal of pharmacology and experimental therapeutics.

[52]  D. DeMets,et al.  Surrogate End Points in Clinical Trials: Are We Being Misled? , 1996, Annals of Internal Medicine.

[53]  Denis Le Bihan,et al.  Diffusion and Perfusion Magnetic Resonance Imaging: Applications to Functional Mri , 1995 .

[54]  N. Alpert,et al.  Pharmacokinetics of 18F-labeled fluconazole in healthy human subjects by positron emission tomography , 1993, Antimicrobial Agents and Chemotherapy.

[55]  Wei Li,et al.  Fast magnetic resonance diffusion‐weighted imaging of acute human stroke , 1992, Neurology.

[56]  N. Alpert,et al.  Pharmacokinetics of 18F-labeled fluconazole in rabbits with candidal infections studied with positron emission tomography. , 1991, The Journal of pharmacology and experimental therapeutics.

[57]  J Kucharczyk,et al.  In vivo diffusion-perfusion magnetic resonance imaging of acute cerebral ischemia. , 1991, Canadian journal of physiology and pharmacology.

[58]  H L Greene,et al.  Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. , 1991, The New England journal of medicine.